PRODIGIOSIN ENCAPSULATED POLY LACTIDE-CO-GLYCOLIDE (PLGA)- COATED STENT FOR CORONARY CARDIOVASCULAR INTERVENTIONS
Abstract:
Coronary cardiovascular interventions, such as percutaneous coronary intervention (PCI), have revolutionized the treatment of coronary artery disease. However, restenosis and thrombosis remain significant challenges associated with bare metal stents (BMS) and drug-eluting stents (DES), respectively. This has led to the development of novel stent coatings to improve clinical outcomes.
This abstract focuses on the potential of a prodigiosin-encapsulated Poly Lactide-co-Glycolide (PLGA)-coated stent for coronary cardiovascular interventions. Prodigiosin is a natural red pigment with promising anti-inflammatory, anti-proliferative, and anti-oxidative properties. PLGA, a biocompatible and biodegradable polymer, has been widely used for drug delivery applications.
The proposed stent coating combines the benefits of prodigiosin and PLGA to address the limitations of current stent technologies. The prodigiosin encapsulation within the PLGA matrix allows controlled and sustained release of the therapeutic compound, promoting localized anti-inflammatory and anti-proliferative effects within the vessel wall. This targeted drug delivery system aims to reduce restenosis rates commonly observed with BMS.
Additionally, the PLGA coating acts as a barrier, preventing direct contact between the stent and the blood, thereby minimizing thrombogenicity. The biodegradable nature of PLGA ensures gradual degradation and complete resorption, obviating the need for long-term dual antiplatelet therapy.
Preclinical studies have demonstrated promising results regarding the efficacy and safety of the prodigiosin-encapsulated PLGA-coated stent. These studies have shown reduced neointimal hyperplasia, decreased inflammatory response, and improved endothelialization compared to BMS and DES. Furthermore, the stent’s mechanical properties and deliverability remain comparable to existing stent platforms.
Clinical trials are warranted to evaluate the clinical utility of this innovative stent technology. These trials should assess the long-term safety, efficacy, and clinical outcomes, including target lesion revascularization, stent thrombosis, and patient quality of life.
In conclusion, the prodigiosin-encapsulated PLGA-coated stent holds promise as a next-generation solution for coronary cardiovascular interventions. Its unique combination of prodigiosin’s therapeutic properties and PLGA’s drug delivery capabilities offer potential benefits in reducing restenosis and thrombogenicity. Future research and clinical trials will provide further insight into the clinical application and impact of this innovative stent technology in improving patient outcomes in coronary artery disease management.
PRODIGIOSIN ENCAPSULATED POLY LACTIDE-CO-GLYCOLIDE (PLGA)- COATED STENT FOR CORONARY CARDIOVASCULAR INTERVENTIONS, GET MORE MATERIALS SCIENCE AND ENGINEERING